Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer A Retrospective Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Joo-Hwan | - |
dc.contributor.author | Yeo, Ja Hyun | - |
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Yang, Jun-Young | - |
dc.contributor.author | Kim, Hyung-Sik | - |
dc.contributor.author | Lee, Woon Kee | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.date.accessioned | 2022-02-03T01:40:28Z | - |
dc.date.available | 2022-02-03T01:40:28Z | - |
dc.date.created | 2022-02-03 | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 0277-3732 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83403 | - |
dc.description.abstract | Objectives: Treatment with trastuzumab and chemotherapy significantly improves the outcome in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). CT-P6 (trastuzumab-pkrb; Herzuma) is a trastuzumab biosimilar approved for the treatment of HER2-positive gastric cancer. In this study, we aimed to compare the efficacy and safety of CT-P6 and reference trastuzumab as first-line treatment for HER2-positive AGC. Materials and Methods: The medical records of 102 patients with HER2-positive AGC treated with first-line trastuzumab-based chemotherapy were retrospectively reviewed. These patients were treated with either reference trastuzumab (n=72) or a biosimilar (n=30). Treatment outcomes, such as objective response rate, progression-free survival (PFS), and overall survival (OS), were compared between the reference and biosimilar groups. Results: The objective response rate of both groups (52.8% and 56.8% in the reference and biosimilar groups, respectively) were comparable (P=0.72). No statistically significant difference was observed with the reference versus biosimilar trastuzumab for PFS (median PFS, 6.9 vs. 5.4 mo; P=0.98) or OS (median OS, 12.3 mo vs. not reached; P=0.42). Safety profiles were similar between the 2 groups. Conclusions: Biosimilar trastuzumab showed equivalent outcome to reference trastuzumab, with similar adverse events. Biosimilar trastuzumab can suitably and safely replace trastuzumab as a reference for the treatment of HER2-positive AGC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | - |
dc.title | Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer A Retrospective Analysis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000746105600003 | - |
dc.identifier.doi | 10.1097/COC.0000000000000887 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, v.45, no.2, pp.61 - 65 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85123878298 | - |
dc.citation.endPage | 65 | - |
dc.citation.startPage | 61 | - |
dc.citation.title | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | - |
dc.citation.volume | 45 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Park, Joo-Hwan | - |
dc.contributor.affiliatedAuthor | Yeo, Ja Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.contributor.affiliatedAuthor | Yang, Jun-Young | - |
dc.contributor.affiliatedAuthor | Kim, Hyung-Sik | - |
dc.contributor.affiliatedAuthor | Lee, Woon Kee | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | trastuzumab | - |
dc.subject.keywordAuthor | biosimilar | - |
dc.subject.keywordAuthor | CT-P6 | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | HER2 | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.